Concepedia

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Lesley Murray, Tinya J. Abrams, Kelly R. Long, Theresa J. Ngai, Lisa Olson, Weiru Hong, Paul Keast, Jacqueline Brassard, A O’Farrell, Julie M. Cherrington,

Clinical & Experimental Metastasis · 2003 · 304 citations · 31 references

DOI

Concepts

References

31

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

, , +15

Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy

Elaine Y. Lin, Andrew Nguyen, Robert G. Russell et al. · The Journal of Experimental Medicine · 2001 · 1.6K citations · Full text

, , +17

The clinical course of bone metastases from breast cancer

RE Coleman, RD Rubens · British Journal of Cancer · 1987 · 1.1K citations · Full text

, , +16

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text

, , +11

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Tinya J. Abrams, Leslie B. Lee, Lesley Murray et al. · PubMed · 2003 · 639 citations

, , +17